Tom Woudenberg1, Stéphane Pelleau2, François Anna3, Mikael Attia4, Françoise Donnadieu2, Alain Gravet5, Caroline Lohmann5, Hélène Seraphin6, Raphaël Guiheneuf6, Catherine Delamare7, Karl Stefic8, Julien Marlet8, Etienne Brochot9, Sandrine Castelain9, Olivier Augereau10, Jean Sibilia11, François Dubos12, Damia Meddour12, Christèle Gras-Le Guen13, Marianne Coste-Burel14, Berthe-Marie Imbert-Marcille14, Anne Chauvire-Drouard15, Cyril Schweitzer16, Amélie Gatin17, Sandra Lomazzi18, Aline Joulié19, Hervé Haas19, Aymeric Cantais20, Frederique Bertholon20, Marie-France Chinazzo-Vigouroux21, Mohamed Si Abdallah22, Laurence Arowas23, Pierre Charneau3, Bruno Hoen24, Caroline Demeret4, Sylvie Van Der Werf25, Arnaud Fontanet26, Michael White27. 1. Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France. Electronic address: tom.woudenberg@pasteur.fr. 2. Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France. 3. Molecular Virology and Vaccinoloy Unit, Department of Virology, Institut Pasteur, Paris, France. 4. Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France. 5. Laboratoire de Microbiologie, Groupement Hospitalier Régional de Mulhouse et Sud-Alsace, Mulhouse, France. 6. Centre Hospitalier Simone Veil de Beauvais, Beauvais, France. 7. CHR Metz Thionville, Metz, France. 8. Service de Bactériologie-Virologie, Hôpital Bretonneau, CHRU de Tours, Tours, France. 9. Service de Virologie, CHU Amiens Picardie, UR 4294 AGIR UPJV, Amiens, France. 10. Service de Microbiologie, Hôpitaux Civils de Colmar, Colmar, France. 11. Laboratoire de Virologie, CHU de Strasbourg, Strasbourg, France. 12. Univ. Lille, CHU Lille, Urgences pédiatriques et maladies infectieuses, Lille, France. 13. Urgences Pédiatrique et Pédiatrie Générale Hopital Mère Enfant CHU de Nantes, Nantes, France. 14. Service de Virologie CHU Nantes, Nantes, France. 15. CHU Nantes, CIC FEA1413, INSERM, Nantes, France. 16. Hôpital d'Enfants, CHRU de Nancy, Vandoeuvre-Les-Nancy, France; EA 3450, DevAH, Université de Lorraine, Vandoeuvre Lès Nancy, France. 17. Pediatric Emergency Unit, Hôpital d'enfants, CHRU Nancy. 18. CRBL, CHRU Nancy, Nancy, France. 19. Urgences pédiatriques et pédiatrie générale, hôpitaux pédiatriques CHU Lenval, Nice. 20. Pediatric Emergency Department, Hospital University of St Etienne, France. 21. Urgences pédiatriques Hopital Clocheville, CHRU de Tours, Tours, France. 22. Agence régionale de santé Hauts-de-France. 23. Investigation Clinique et Accès aux Ressources Biologiques (ICAReB), Center for Translational Research, Institut Pasteur, Paris, France. 24. Direction de la recherche médicale, Institut Pasteur, Paris, France. 25. Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur, CNRS UMR 3569, Paris, France; National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France. 26. Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Paris, France; PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France. Electronic address: arnaud.fontanet@pasteur.fr. 27. Infectious Disease Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France; Malaria: Parasites and Hosts Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France. Electronic address: michael.white@pasteur.fr.
Abstract
BACKGROUND: Children are underrepresented in the COVID-19 pandemic and often experience milder disease than adolescents and adults. Reduced severity is possibly due to recent and more frequent seasonal human coronaviruses (HCoV) infections. We assessed the seroprevalence of SARS-CoV-2 and seasonal HCoV specific antibodies in a large cohort in north-eastern France. METHODS: In this cross-sectional seroprevalence study, serum samples were collected from children and adults requiring hospital admission for non-COVID-19 between February and August 2020. Antibody responses to SARS-CoV-2 and seasonal HCoV (229E, HKU1, NL63, OC43) were assessed using a bead-based multiplex assay, Luciferase-Linked ImmunoSorbent Assay, and a pseudotype neutralisation assay. FINDINGS: In 2,408 individuals, seroprevalence of SARS-CoV-2-specific antibodies was 7-8% with three different immunoassays. Antibody levels to seasonal HCoV increased substantially up to the age of 10. Antibody responses in SARS-CoV-2 seropositive individuals were lowest in adults 18-30 years. In SARS-CoV-2 seronegative individuals, we observed cross-reactivity between antibodies to the four HCoV and SARS-CoV-2 Spike. In contrast to other antibodies to SARS-CoV-2, specific antibodies to sub-unit 2 of Spike (S2) in seronegative samples were highest in children. Upon infection with SARS-CoV-2, antibody levels to Spike of betacoronavirus OC43 increased across the whole age spectrum. No SARS-CoV-2 seropositive individuals with low levels of antibodies to seasonal HCoV were observed. INTERPRETATION: Our findings underline significant cross-reactivity between antibodies to SARS-CoV-2 and seasonal HCoV, but provide no significant evidence for cross-protective immunity to SARS-CoV-2 infection due to a recent seasonal HCoV infection. In particular, across all age groups we did not observe SARS-CoV-2 infected individuals with low levels of antibodies to seasonal HCoV. FUNDING: This work was supported by the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur, by the French Government's Investissement d'Avenir program, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (Grant No. ANR-10-LABX-62-IBEID), and by the REACTing (Research & Action Emerging Infectious Diseases), and by the RECOVER project funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101003589, and by a grant from LabEx IBEID (ANR-10-LABX-62-IBEID).
BACKGROUND:Children are underrepresented in the COVID-19 pandemic and often experience milder disease than adolescents and adults. Reduced severity is possibly due to recent and more frequent seasonal human coronaviruses (HCoV) infections. We assessed the seroprevalence of SARS-CoV-2 and seasonal HCoV specific antibodies in a large cohort in north-eastern France. METHODS: In this cross-sectional seroprevalence study, serum samples were collected from children and adults requiring hospital admission for non-COVID-19 between February and August 2020. Antibody responses to SARS-CoV-2 and seasonal HCoV (229E, HKU1, NL63, OC43) were assessed using a bead-based multiplex assay, Luciferase-Linked ImmunoSorbent Assay, and a pseudotype neutralisation assay. FINDINGS: In 2,408 individuals, seroprevalence of SARS-CoV-2-specific antibodies was 7-8% with three different immunoassays. Antibody levels to seasonal HCoV increased substantially up to the age of 10. Antibody responses in SARS-CoV-2 seropositive individuals were lowest in adults 18-30 years. In SARS-CoV-2 seronegative individuals, we observed cross-reactivity between antibodies to the four HCoV and SARS-CoV-2Spike. In contrast to other antibodies to SARS-CoV-2, specific antibodies to sub-unit 2 of Spike (S2) in seronegative samples were highest in children. Upon infection with SARS-CoV-2, antibody levels to Spike of betacoronavirus OC43 increased across the whole age spectrum. No SARS-CoV-2 seropositive individuals with low levels of antibodies to seasonal HCoV were observed. INTERPRETATION: Our findings underline significant cross-reactivity between antibodies to SARS-CoV-2 and seasonal HCoV, but provide no significant evidence for cross-protective immunity to SARS-CoV-2 infection due to a recent seasonal HCoV infection. In particular, across all age groups we did not observe SARS-CoV-2 infected individuals with low levels of antibodies to seasonal HCoV. FUNDING: This work was supported by the « URGENCE COVID-19 » fundraising campaign of Institut Pasteur, by the French Government's Investissement d'Avenir program, Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases (Grant No. ANR-10-LABX-62-IBEID), and by the REACTing (Research & Action Emerging Infectious Diseases), and by the RECOVER project funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 101003589, and by a grant from LabEx IBEID (ANR-10-LABX-62-IBEID).
Authors: David J Gregory; Augustin Vannier; Akiro H Duey; Tyler J Roady; Richard K Dzeng; Maia N Pavlovic; Michael H Chapin; Sonia Mukherjee; Hannah Wilmot; Nic Chronos; Richelle C Charles; Edward T Ryan; Regina C LaRocque; Tyler E Miller; Wilfredo F Garcia-Beltran; Julia C Thierauf; A John Iafrate; Steven Mullenbrock; Mark D Stump; Randall K Wetzel; Roberto D Polakiewicz; Vivek Naranbhai; Mark C Poznansky Journal: Virulence Date: 2022-12 Impact factor: 5.428
Authors: Rodrigo Borrega; Diana K S Nelson; Anatoliy P Koval; Nell G Bond; Megan L Heinrich; Megan M Rowland; Raju Lathigra; Duane J Bush; Irina Aimukanova; Whitney N Phinney; Sophia A Koval; Andrew R Hoffmann; Allison R Smither; Antoinette R Bell-Kareem; Lilia I Melnik; Kaylynn J Genemaras; Karissa Chao; Patricia Snarski; Alexandra B Melton; Jaikin E Harrell; Ashley A Smira; Debra H Elliott; Julie A Rouelle; Gilberto Sabino-Santos; Arnaud C Drouin; Mambu Momoh; John Demby Sandi; Augustine Goba; Robert J Samuels; Lansana Kanneh; Michael Gbakie; Zoe L Branco; Jeffrey G Shaffer; John S Schieffelin; James E Robinson; Dahlene N Fusco; Pardis C Sabeti; Kristian G Andersen; Donald S Grant; Matthew L Boisen; Luis M Branco; Robert F Garry Journal: Viruses Date: 2021-11-21 Impact factor: 5.048
Authors: Meryem Seda Ercanoglu; Lutz Gieselmann; Sabrina Dähling; Nareshkumar Poopalasingam; Susanne Detmer; Manuel Koch; Michael Korenkov; Sandro Halwe; Michael Klüver; Veronica Di Cristanziano; Hanna Janicki; Maike Schlotz; Johanna Worczinski; Birgit Gathof; Henning Gruell; Matthias Zehner; Stephan Becker; Kanika Vanshylla; Christoph Kreer; Florian Klein Journal: iScience Date: 2022-02-19
Authors: Vera S Kichatova; Fedor A Asadi Mobarkhan; Ilya A Potemkin; Sergey P Zlobin; Oksana M Perfilieva; Vladimir T Valuev-Elliston; Alexander V Ivanov; Sergey A Solonin; Mikhail A Godkov; Maria G Belikova; Mikhail I Mikhailov; Karen K Kyuregyan Journal: Microorganisms Date: 2022-02-12
Authors: Sebastian Wirsching; Laura Harder; Markus Heymanns; Britta Gröndahl; Katja Hilbert; Frank Kowalzik; Claudius Meyer; Stephan Gehring Journal: Front Immunol Date: 2022-04-20 Impact factor: 8.786